Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces

Letter to Editor

Authors

1 Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Recently, Wuhan, China became the epicenter for the outbreak of novel coronavirus pneumonia (COVID-19). No specific agents are available for treating COVID-19 while some agents such as antivirals, chloroquine, and immunomodulatory agents are under investigation.
In vitro and in vivo studies showed that thalidomide impairs the synthesis of tumor necrosis factor alpha (TNF-alpha). It increases peripheral blood CD8+ T cells, plasma interleukin 12 (IL-12) levels, interferon-γ production, and cytotoxic activity. Anti-inflammatory effects of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice showed that thalidomide greatly improves the survival rate, reduces the infiltration of inflammatory cells, cytokine (e.g., IL-6, TNF-α), and chemokine (chemokine ligand 5, C-X-C motif chemokine 10) levels, and inhibits the activated p-NFκB p6. Given the beneficial effects of thalidomide, it is necessary to try it in COVID-19 cases as a therapeutic agent. It is recommended that large clinical trials be designed to find the efficacy and safety of thalidomide in COVID-19.

Graphical Abstract

Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces

Keywords

Main Subjects


References
(1) Wu Z and Mc Googan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for
Disease Control and Prevention. JAMA (2020) 2020: E1-E4.
(2) Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia Ja, Yu T, Zhang X and Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus
pneumonia in Wuhan, China: a descriptive study. Lancet (2020) 395: 507-13.
(3) Sahraei Z, Shabani M, Shokouhi S and Saffaei A. Aminoquinolines against Coronavirus Disease 2019 (COVID-19): chloroquine or Hydroxychloroquine. Int. J. Antimicrob. Agents (2020) 2020: 105945.
(4) Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res. C Embryo Today (2015) 105: 140-56.
(5) Mujagic H, Chabner BA and Mujagic Z. Mechanisms of action and potential therapeutic uses of thalidomide. Croat. Med. J. (2002) 43: 274-85.
(6) Tabata C, Tabata R, Takahashi Y, Nakamura K and Nakano T. Thalidomide prevents cigarette smoke extract-induced lung damage in mice. Int. Immunopharmacol. (2015) 25: 511-7.
(7) Dong X, Li X, Li M, Chen M, Fan Q and Wei W. Antiinflammation and antioxidant effects of thalidomide on pulmonary fibrosis in mice and human lung fibroblasts. Inflammation (2017) 40: 1836-46.
(8) Amirshahrokhi K. Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice. Int. Immunopharmacol. (2013) 17: 210-15.
(9) Uthoff K, Zehr KJ, Gaudin PB, Kumar P, Cho PW, Vogelsang G, Hruban RH, Baumgartner WA and Stuart RS. Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Ann. Thorac. Surg. (1995) 59: 277-82.
(10) Dong X, Li X, Li M, Chen M, Fan Q and Wei W. Inhibitory effects of thalidomide on bleomycin- induced pulmonary fibrosis in rats via regulationof thioredoxin reductase and inflammations. Am. J.Transl. Res. (2017) 9: 4390-401.
(11) Hanekom WA, Hughes J, Haslett PAJ, Apolles P,Ganiso V, Allin R, Goddard E, Hussey GD andKaplan G. The immunomodulatory effects ofthalidomide on human immunodeficiency virus– infected children. J. Infect. Dis. (2001) 184: 1192-6.
(12) Vergara TRC, Samer S, Santos-Oliveira JR, Giron LB, Arif MS, Silva-Freitas ML, Cherman LA, Treitsman MS, Chebabo A, Sucupira MCA, Da- Cruz AM and Diaz RS. Thalidomide is associatedwith increasedcell activation and inflammationin antiretroviral-naive HIV-infected individuals in a randomised clinical trial of efficacy and safety. EBioMedicine (2017) 23: 59-67.
(13) Chen C, Qi F, Shi K, Li Y, Li J Chen Y, Pan J, Zhou T, Lin X, Zhang J, Luo Y, Li X and Xia J. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia. Preprints
(2020) 2020: 1-6